{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-036148","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.475929+00:00","generated_at":"2026-06-04T12:54:20.166959+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cyclacel posts FY2023 net loss $22.6M; cash runway only into Q2 2024","bullets":["Net loss $22.6M for FY2023 vs $21.2M in FY2022; R&D expenses $19.2M vs $20.3M.","Cash and equivalents $3.4M at Dec 31, 2023; pro forma $6.3M incl $2.9M UK R&D tax credit received after year end.","Company expects available cash to fund planned programs only into Q2 2024.","On track to start oral fadraciclib Phase 2 proof-of-concept in 1H 2024; final Phase 1 data expected.","Plogosertib to switch to new oral formulation; preclinical data support precision medicine in ARID1A/SMARCA-mutated cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-036148","json":"https://secwatch.observer/filing/0001104659-24-036148.json","markdown":"https://secwatch.observer/filing/0001104659-24-036148.md","text":"https://secwatch.observer/filing/0001104659-24-036148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924036148/0001104659-24-036148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924036148/tm249239d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:54:20.166959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8181d65003aff81f8d6ee906963061f915ea2108","claim":"Bio Green Med Solution, Inc. reported the year ended December 31, 2023 results: net income $22.6 million.","evidence_excerpt":"Net loss for the three months and year ended December 31, 2023, was $5.3 million and $22.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924036148/0001104659-24-036148-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$22.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"db95272f4c940495669025e09867fc8428e9e90a","claim":"Bio Green Med Solution, Inc. reported the three months ended December 31, 2023 results: net income $5.3 million.","evidence_excerpt":"Net loss for the three months and year ended December 31, 2023, was $5.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924036148/0001104659-24-036148-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Net income","value":"$5.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}